-
Document de presse | 2015.01.13
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
In association with Imperial College London, scientists at the Institut Pasteur and CNRS have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation. These results were...
-
News | 2017.01.12
Yellow fever: using modeling to optimize the use of vaccine stocks
In December 2015 a yellow fever epidemic broke out in Angola, subsequently giving rise to 7,300 suspected cases and nearly 400 deaths. A group of scientists from Oxford University and the Institut Pasteur conducted research into the geographical spread of this epidemic, with the aim of containing this outbreak and optimizing the use of the limited available vaccine stock.According to the World...
-
Article | 2020.07.07
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
-
Document de presse | 2005.11.27
Glaxosmithkline Biologicals Licenses Institut Pasteur Technology to develop AIDS Vaccine; Innovative Public-Private Partenership will use Measles Vaccine As starting point
Using an ancient scourge to combat a new one, researchers from GlaxoSmithKline Biologicals and the Institut Pasteur announced a new European collaboration to develop an AIDS vaccine by fusing genes from the human immunodeficiency virus (HIV) onto an existing measles vaccine. Press release Paris, november 28, 2005 GSK Biologicals will license the measles vaccine vector...
-
Article | 2020.06.22
Development of novel nano-based multi-epitope vaccine against coronavirus SARS-CoV-2 - Generation of Humanized NSG transfer mouse model for vaccine testing
Aim: We hypothesize that it may be possible to generate protective anti-SARS-CoV-2 immuneresponse in humanized NSG transfer mouse model. This will be achieved by administering to them of lipid-based nanoparticles carrying peptide molecules, comprising dominant immunogenic B and T cell epitopes from coronavirus SARS-CoV-2. The epitopes will be predicted by EpiDOCK server for evaluation of...
-
News | 2023.07.24
Rabies: elucidating the disease to limit spread and prepare for future outbreaks
Although rabies control has progressed considerably since Louis Pasteur first trialed his vaccine, the disease continues to kill thousands of people who do not have access to treatment. Scientists have traced the evolution of the disease worldwide over different eras in a bid to improve our understanding of and preparedness for emerging infectious diseases.
-
Fiche maladie | 2015.10.06
MERS-CoV
A new respiratory virus emerged in Saudi Arabia in 2012. It was named MERS-CoV, or Middle East Respiratory Syndrome Coronavirus, and it affects the respiratory tract, causing fever and a cough and proving fatal in 30% of cases. The virus has since been reported in several countries throughout the Middle East. In all, 1,219 cases have been diagnosed, leading to 449 deaths. Several cases have been...
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Document de presse | 2021.01.25
COVID-19: progress update on the Institut Pasteur's scientific response and vaccine candidate research programs
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics, pathophysiology, epidemiology, modeling, therapeutic research and vaccine research. A number of research programs to find a vaccine for SARS-CoV-2, the virus responsible for the COVID-19 epidemic, are under way. In light of the intermediate results...